Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05412277 · ClinicalTrials.gov registry record · NA
VIA Disc Nucleus Pulposus Older Patients Pilot
A NA study of Low Back Pain and Degenerative Disc Disease, sponsored by VIVEX Biologics.
- Active
- Registry status
- NA
- Development phase
- 21
- Enrollment target
- 5
- Study locations
NCT05412277: Active NA study of Low Back Pain and Degenerative Disc Disease, sponsored by VIVEX Biologics.
NCT05412277 is a NA study of Low Back Pain and Degenerative Disc Disease that is active but no longer recruiting, run by VIVEX Biologics. The registered enrollment target is 21 participants, below the 504-participant average among 122 other Low Back Pain trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05412277, a NA study of Low Back Pain and Degenerative Disc Disease, is active but no longer recruiting, sponsored by VIVEX Biologics.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
- 5
- Study locations
Study Summary
VIA Disc NP is a non-surgical intervention intended to supplement the nucleus pulposus tissue in degenerated intervertebral discs.
Conditions Studied
Interventions
- OTHER VIA Disc Nucleus Pulposus Allograft
Study Locations (5)
Florida
- Florida Spine & Pain Specialists - Tampa
Georgia
- Southern Pain and Spine Associates - Newnan
Louisiana
- Paradigm Spine Care & Interventional Pain - Slidell
North Carolina
- Center for Clinical Research - Winston-Salem
Texas
- Precision Spine Care - Tyler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2022-10-17 |
| Est. Completion | 2024-12-31 |
| Phase | NA |
What the registry record for NCT05412277 still lists
NCT05412277 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 504-participant average among 122 other Low Back Pain trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Low Back Pain appearing as the primary indexed condition, and to 1 intervention - of which VIA Disc Nucleus Pulposus Allograft is the first listed.
NCT05412277 lists 5 locations in 5 states (Florida, Georgia, Louisiana).
Frequently Asked Questions
What is clinical trial NCT05412277 about?
NCT05412277 is a clinical study titled "VIA Disc Nucleus Pulposus Older Patients Pilot". VIA Disc NP is a non-surgical intervention intended to supplement the nucleus pulposus tissue in degenerated intervertebral discs.
What is the current status of trial NCT05412277?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 21 participants. The study started on 2022-10-17. Estimated completion is 2024-12-31.
What conditions does trial NCT05412277 study?
This clinical trial studies the following conditions: Low Back Pain, Degenerative Disc Disease, Disc Degeneration.
What interventions are being tested in trial NCT05412277?
The interventions under investigation include: VIA Disc Nucleus Pulposus Allograft (OTHER).
Who is sponsoring clinical trial NCT05412277?
This trial is sponsored by VIVEX Biologics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05412277 being conducted?
This trial has 5 study locations across Florida, Georgia, Louisiana, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Low Back Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05412277's enrollment target sits among peer trials
21 117th of 122 higher than 6 of 122 other Low Back Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Low Back Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Erector Spinae Plane Block for Acute Back Pain in the Emergency Department
RECRUITING · NA
-
A Multi-Site Feasibility Trial of Embedded Emergency Department Physical Therapy
RECRUITING · NA
-
Ischemic Preconditioning in Osteoarthritis and Back Pain
RECRUITING · NA
-
Feasibility of Identifying Brain Mechanisms of Qigong and Behavioral Outcomes After Qigong Practice in People With Chronic Low Back Pain
RECRUITING · NA
-
Neural Mechanisms of Meditation for Opioid-Treated Chronic Low Back Pain
RECRUITING · NA
-
Perspectives on Spinal Manipulative Therapy for Low Back Pain
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI